The GenomesDAO Roadmap
The 7 day countdown to our launch on Miso by Sushi has begun. Here is what we have been building and what we have planned.
#1 — MISO Public $GENE Sale
16th November Max cap — 999 ETH following our oversubscribed sellout 100 ETH presale miso.sushi.com
#2 — NFT Project Launch
To find out more details — Join our discord — We WILL be releasing some more alpha this week :)
#3 — Company Operations in Q4
1.Scale up Team
2. Apply tokenomics across platform
We have spent the last 3 years working with bioinformaticians and encryption experts, both in the GenomesDAO team and AMD to ensure the most secure storage of your most personal data.
In executing our proofs of computation and allowing repeat consent using mobile blockchain wallets, that are already live on the appstore.
We now need to allow for our freshly minted $GENE token to be used throughout the platform. A reminder the token will be deflationary and a percentage will be burned every time a sequencing kit is bought using $GENE.
Our Core priorities for 2022
#1–10,000 Genomes is our AMD SEV-ES vaults
We have several ways to achieve this. Firstly, our 10,000 NFT project to be announced this week, if successful will result in 10,000 Genomes being secured in GenomesDAO vaults.
We also have partnerships with 2 national genome sequencing initiatives to power repeat consent of genomic queries across their citizen cohorts, and are expanding our business development efforts globally in 2022.
#2 — Brokerage of Data to pharma — aka — making passive income for our users
We have done our market research with pharmaceutical companies, who are the ones who told us that genomic querying will become interesting for them within the global general public at 10,000 genomes. This is why we have this short term target and this is when we will begin brokering queries of users data that they can accept payment for, or turn down.
We will also be working with our business development leads to allow pharmaceutical companies to bulk buy $GENE, our deflationary utility token, allowing them to make more queries for less money, locking up $GENE token supply at the same time.
#3 — Launch of GenomesDAO secure Organisational Platform (Rare Disease Charities etc)
We at GenomesDAO aim to supercharge rare disease research and development and accelerate the process of bringing new therapies to those patients that need them most.
One rare disease may only affect a handful of people, whereas another may touch as many as 245,000. However, the majority of these patients are members and part of the patient groups of national and international rare disease organisations. These organisations vary in size and organisational complexity but all provide information, advice and support services to their rare disease patient group, and fund vital research into their condition. There are around 250 of these organisations throughout the UK, 830 in Europe and 280 in the US.
Most of these organisations understand the benefit that genomics will bring to research into their condition, but many do not know how to get involved and the majority of their patient groups have not had their DNA sequenced. We want to change this!
We work with these rare disease organisations to create secure and patient-owned whole genome sequence databases and connect these with researchers from academia and industry.
We have two models of doing so:
- Rare disease organisations fund sequencing of their patient groups in return for revenue share during data brokerage.
- Research organisation funds sequencing of the patient group in return for priority access to the database.
In both models, our platform provides researchers from both academia and industry with access to invaluable genomic datasets by connecting them directly with rare disease patients. However, we do so in a model that incentivises data sharing by ensuring equitable compensation, transparency, data privacy, security and ownership rights of individual patients.
GenomesDAO technology can solve these 2 key problems:
- Making rare disease genomic datasets openly available to researchers
- Protecting individual patient’s sensitive genomic data
This is achieved by giving patients true ownership of their personal virtual ‘DNA Vault’ to which they can control access to from their mobile device. Following whole genome sequencing, patient genomic data is uploaded directly, encrypted and securely stored within these fully encrypted and virtualized cloud-data storage containers.
These ‘DNA Vaults’ have been built in collaboration with Advanced Micro Devices (AMD) and Consensys, and harness cutting-edge secure encryption virtualisation (SEV) and blockchain technologies to secure the data and manage access control. No one is able to access these ‘DNA Vaults’, including GenomesDAO as a technology provider, until explicit permission is given to third-party researchers from the private key holder (the individual).
When a patient grants a third-party researcher access to their data, their raw data never leaves their secure ‘DNA Vault’. Only anonymised ‘snippets’ are shared that cannot be reverse engineered to re-identify the individual.
Our model allows users to give researchers repeat and informed consent access to their genomic data without compromising their privacy. It confers benefits to both the individual patient, the rare disease organisation and rare disease researchers.
#4 — Expansion of Tests Available — Open API to 3rd Parties
An open system will benefit from the wisdom of others. If you build genomic sequencing query tests, you can monetise them on our platform, and we’d love to hear from you, whether it’s a fun test — or a medically assured healthcare cohort study.
We already have some fantastic partnerships in the space. We are looking to partner with more DeFi protocols for treasury growth and liquidity — If you have any questions about this, or our upcoming public sale, join us in our discord at discord.gg/genomes